ASRS 2019 Street Team: Raj K. Maturi, MD

Conference|ASRS

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.

Related Videos
How to diagnose geographic atrophy earlier
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Related Content

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Putting in practice retina innovations amid a pandemic

August 28th 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Putting in practice retina innovations amid a pandemic

August 28th 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023

Retinal scans provide a non-invasive, inexpensive method to track aging

March 30th 2023

Putting in practice retina innovations amid a pandemic

August 28th 2020

COPHy 2023: Debating the value of home monitoring as a management option for AMD

March 25th 2023

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment uveitis post-FAi

July 29th 2020

LumiThera reveals sustained vision improvement for 24 months in dry AMD clinical trial data

March 17th 2023

COPHy 2023 sets stage for evidence-based debates and discussions

March 15th 2023
© 2023 MJH Life Sciences

All rights reserved.